Zelboraf is indicated for the treatment of metastatic melanoma and Erdheim-Chester disease.
The Signant Health Partner Program aims to enable CROs to better serve sponsors across the areas of patient data, patient experience, clinical supplies, and endpoint quality solutions.
CROs will also benefit from commercial and operational advantages by becoming a Signant partner.
CROs offer full services across the entire drug development process and will gain exclusive commercial terms and business development support.
Other benefits include joint marketing, clinical and scientific expertise, product training, and dedicated resources for governance.
Signant Health chief commercial officer Chris Crucitti said: “This programme puts in place the infrastructure needed to ensure the success of our CRO partners across Signant’s solution portfolio.
“We will remain ever committed to the traditional support of our partners via protocol design and optimisation, eCOA data collection, data quality oversight, patient engagement, eConsent, and clinical supply management.
“The time is right for us to make a landmark investment in our partners so that together we can more powerfully impact data quality and clinical trial execution.”
The majority of clinical research activities are being outsourced by pharmaceutical companies to CROs, resulting in a large demand for companies to deliver technology in support of services.
The Signant Health Partner Program has been designed to extend the company’s experience to its partners in clinical and scientific practices, allowing CROs to deliver the accurate endpoint data across its solutions.
In June this year, CRF Bracket, a merged entity of CRF Health and Bracket, was launched as Signant Health.
Signant claims to simplify the process of global drug development by combining eCOA, patient Engagement, eConsent, clinical supplies, and endpoint quality into the industry’s patient-centric suite.